PAVAN REDDY to Adolescent
This is a "connection" page, showing publications PAVAN REDDY has written about Adolescent.
Connection Strength
0.182
-
Vorinostat plus tacrolimus/methotrexate to prevent GVHD after myeloablative conditioning, unrelated donor HCT. Blood. 2017 10 12; 130(15):1760-1767.
Score: 0.036
-
Cognitive Functioning in Vorinostat-Treated Pediatric and Young Adult Patients Over the First 180 Days After Hematopoietic Stem Cell Transplant. Pediatr Blood Cancer. 2026 Jun; 73(6):e70259.
Score: 0.016
-
Prevention and Treatment of Acute Graft-versus-Host Disease in Children, Adolescents, and Young Adults. Biol Blood Marrow Transplant. 2020 05; 26(5):e101-e112.
Score: 0.011
-
A Phase 2 Study of Pembrolizumab during Lymphodepletion after Autologous Hematopoietic Cell Transplantation for Multiple Myeloma. Biol Blood Marrow Transplant. 2019 08; 25(8):1492-1497.
Score: 0.010
-
Assessment of Individual versus Composite Endpoints of Acute Graft-versus-Host Disease in Determining Long-Term Survival after Allogeneic Transplantation. Biol Blood Marrow Transplant. 2019 08; 25(8):1682-1688.
Score: 0.010
-
MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD. Blood. 2018 06 21; 131(25):2846-2855.
Score: 0.009
-
An early-biomarker algorithm predicts lethal graft-versus-host disease and survival. JCI Insight. 2017 02 09; 2(3):e89798.
Score: 0.009
-
Infectious Risk after Allogeneic Hematopoietic Cell Transplantation Complicated by Acute Graft-versus-Host Disease. Biol Blood Marrow Transplant. 2017 Mar; 23(3):522-528.
Score: 0.009
-
Combination Therapy for Graft-versus-Host Disease Prophylaxis with Etanercept and Extracorporeal Photopheresis: Results of a Phase II Clinical Trial. Biol Blood Marrow Transplant. 2016 May; 22(5):862-8.
Score: 0.008
-
FLT3 mutational status is an independent risk factor for adverse outcomes after allogeneic transplantation in AML. Bone Marrow Transplant. 2016 Apr; 51(4):511-520.
Score: 0.008
-
Participation in clinical research: perspectives of adult patients and parents of pediatric patients undergoing hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2014 Oct; 20(10):1604-11.
Score: 0.007
-
TNF-inhibition with etanercept for graft-versus-host disease prevention in high-risk HCT: lower TNFR1 levels correlate with better outcomes. Biol Blood Marrow Transplant. 2012 Oct; 18(10):1525-32.
Score: 0.006
-
Plasma biomarkers of lower gastrointestinal and liver acute GVHD. Blood. 2012 Mar 22; 119(12):2960-3.
Score: 0.006
-
Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease. Blood. 2011 Dec 15; 118(25):6702-8.
Score: 0.006
-
Clofarabine and busulfan conditioning facilitates engraftment and provides significant antitumor activity in nonremission hematologic malignancies. Blood. 2011 Oct 13; 118(15):4258-64.
Score: 0.006
-
Frequency of CD4(+)CD25(hi)FOXP3(+) regulatory T cells has diagnostic and prognostic value as a biomarker for acute graft-versus-host-disease. Biol Blood Marrow Transplant. 2010 Jul; 16(7):907-14.
Score: 0.005
-
Elafin is a biomarker of graft-versus-host disease of the skin. Sci Transl Med. 2010 Jan 06; 2(13):13ra2.
Score: 0.005
-
A biomarker panel for acute graft-versus-host disease. Blood. 2009 Jan 08; 113(2):273-8.
Score: 0.005
-
Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease. Blood. 2008 Feb 15; 111(4):2470-5.
Score: 0.005
-
Pilot trial on the use of etanercept and methylprednisolone as primary treatment for acute graft-versus-host disease. Biol Blood Marrow Transplant. 2005 Sep; 11(9):680-7.
Score: 0.004